,address1,address2,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Dr. Paul B.  Bolno M.B.A., M.D., MBA', 'age': 48, 'title': 'Pres, CEO & Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1102777, 'exercisedValue': 0, 'unexercisedValue': 989993}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
1,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Mr. Kyle B.  Moran CFA', 'age': 51, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 677867, 'exercisedValue': 0, 'unexercisedValue': 113000}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
2,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Dr. Chandra  Vargeese Ph.D.', 'age': 61, 'title': 'CTO & Head of Platform Discovery Sciences', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 710054, 'exercisedValue': 0, 'unexercisedValue': 930957}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
3,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Kate  Rausch', 'title': 'Head of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
4,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Ms. Linda  Rockett J.D.', 'title': 'Gen. Counsel', 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
5,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Dr. Christopher  Francis Ph.D.', 'age': 44, 'title': 'Sr. VP of Corp. Devel. & Head of Emerging Areas', 'yearBorn': 1978, 'fiscalYear': 2018, 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
6,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Dr. Sridhar  Vaddeboina Ph.D.', 'title': 'Sr. VP of Chemistry, Manufacturing & Controls', 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
7,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Ms. Anne-Marie  Li-Kwai-Cheung', 'title': 'Chief Devel. Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
8,Marina One East Tower,7 Straits View No.12-00,Singapore,018936,Singapore,65 6236 3388,https://www.wavelifesciences.com,Biotechnology,Healthcare,"Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.",250,"{'maxAge': 1, 'name': 'Dr. Hsiu-Chiung  Yang Ph.D.', 'title': 'Sr. VP of Translational Medicine', 'exercisedValue': 0, 'unexercisedValue': 0}",7,2,7,3,4,1693526400,1672444800,86400,2,5.21,5.27,4.99,5.57,5.21,5.27,4.99,5.57,0.0,-0.947786,-5.192308,984093,984093,382146,277990,277990,5.11,5.4,900,2900,534509792,3.04,7.12,14.620471,4.4528,4.43345,0.0,0.0,USD,404569600,0.0,42513311,98983296,3415710,3447629,1690761600,1693440000,0.0345,0.21219,0.71678,16.43,0.0769,-0.525,1672444800,1703980800,1688083200,-131222000,-1.32,-1.04,11.066,-3.104,NGM,EQUITY,WVE,WVE,Wave Life Sciences Ltd.,Wave Life Sciences Ltd.,1447252200,America/New_York,EDT,-14400000,5.4,17.0,4.0,7.69,6.25,2.5,buy,8,172974000,1.748,-130349000,35160000,1.234,1.317,36559000,0.369,-0.3841,9367500,-10821000,57.949,-2.36295,0.0,-3.7260299,USD,
